65
Participants
Start Date
March 9, 2009
Primary Completion Date
February 27, 2014
Study Completion Date
October 19, 2015
AMG 386 30 mg/kg, Paclitaxel and Trastuzumab
AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
AMG 386 30 mg/kg, Capecitabine and Lapatinib
AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
AMG 386 10 mgkg, Paclitaxel and Trastuzumab
AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
AMG 386 10 mg/kg, Capecitabine and Lapatinib
AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
Research Site, Wilrijk
Research Site, Leuven
Research Site, Liège
Research Site, New York
Research Site, New City
Research Site, Nyack
Research Site, Great Neck
Research Site, Marseille
Research Site, Caen
Research Site, Toulouse
Research Site, Bordeaux
Research Site, Boca Raton
Research Site, Nantes
Research Site, Middletown
Research Site, Iowa City
Research Site, Minneapolis
Research Site, Pierre Bénite Cedex
Research Site, Tucson
Research Site, La Roche-sur-Yon
Research Site, Albuquerque
Research Site, Boston
Research Site, Lebanon
Research Site, Lebanon
Lead Sponsor
Amgen
INDUSTRY